GSK 6-K: CEO, CFO acquire Ordinary Shares at £18.1420

Rhea-AI Filing Summary

GSK plc reported routine insider share acquisitions by multiple senior executives under its Share Reward Plan. The transactions covered Ordinary Shares of 31 ¼ pence each (ISIN: GB00BN7SWP63) at £18.1420 per share on the London Stock Exchange.

Participants included CEO Emma Walmsley and CFO Julie Brown, each acquiring 14 Ordinary Shares (7 partnership and 7 matching). Other executives—James Ford, Sally Jackson, Regis Simard, Philip Thomson, and Victoria Whyte—also acquired 14 shares each on 2025-11-11. David Redfern acquired 12 shares (6 partnership and 6 matching). These are standard plan-related purchases disclosed via Form 6-K.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

​

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.1420	7 (partnership shares)
		£18.1420	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.1420
e)	Date of the transaction	2025-11-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.1420	7 (partnership shares)
		£18.1420	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.1420
e)	Date of the transaction	2025-11-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.1420	7 (partnership shares)
		£18.1420	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.1420
e)	Date of the transaction	2025-11-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.1420	7 (partnership shares)
		£18.1420	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.1420
e)	Date of the transaction	2025-11-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.1420	6 (partnership shares)
		£18.1420	6 (matching shares)
d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £18.1420
e)	Date of the transaction	2025-11-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.1420	7 (partnership shares)
		£18.1420	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.1420
e)	Date of the transaction	2025-11-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.1420	7 (partnership shares)
		£18.1420	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.1420
e)	Date of the transaction	2025-11-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.1420	7 (partnership shares)
		£18.1420	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.1420
e)	Date of the transaction	2025-11-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.1420	7 (partnership shares)
		£18.1420	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.1420
e)	Date of the transaction	2025-11-11
f)	Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: November 13, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What did GSK (GSK) disclose in this 6-K?

GSK disclosed acquisitions of Ordinary Shares by several executives under the Company’s Share Reward Plan at £18.1420 per share on the London Stock Exchange.

Which GSK executives acquired shares and in what amounts?

Emma Walmsley and Julie Brown each acquired 14 shares. James Ford, Sally Jackson, Regis Simard, Philip Thomson, and Victoria Whyte each acquired 14 shares. David Redfern acquired 12 shares.

What was the transaction date and venue for the GSK insider purchases?

All reported acquisitions occurred on 2025-11-11 and were conducted on the London Stock Exchange (XLON).

At what price were the GSK Ordinary Shares acquired?

Each reported acquisition was at £18.1420 per share.

What share plan was used for these GSK insider acquisitions?

The shares were acquired under GSK’s Share Reward Plan, comprising partnership and matching shares.

What class of GSK securities was involved?

Ordinary shares of 31 ¼ pence each, ISIN GB00BN7SWP63.